Morgan Stanley Forecasts Strong Price Appreciation for IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories (NASDAQ:IDXX) had its price target raised by Morgan Stanley from $805.00 to $810.00 in a report released on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley‘s price objective would indicate a potential upside of 20.25% from the stock’s current price.

IDXX has been the subject of several other reports. KeyCorp assumed coverage on IDEXX Laboratories in a research report on Monday, October 12th. They set a “sector weight” rating for the company. JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday, October 16th. Barclays cut their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. UBS Group upped their price objective on IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research report on Tuesday. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Eight equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $728.17.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded up $1.94 during midday trading on Tuesday, hitting $673.58. The company had a trading volume of 317,733 shares, compared to its average volume of 573,822. The company’s 50 day simple moving average is $536.56 and its 200 day simple moving average is $573.88. IDEXX Laboratories has a 52-week low of $500.61 and a 52-week high of $769.98. The stock has a market cap of $53.06 billion, a price-to-earnings ratio of 47.44 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.71 by $0.25. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.22 earnings per share. Research analysts anticipate that IDEXX Laboratories will post 14.81 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.79% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IDXX. Bank of New York Mellon Corp acquired a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of IDEXX Laboratories by 4.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock valued at $479,844,000 after buying an additional 39,700 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after buying an additional 288,471 shares during the period. Dimensional Fund Advisors LP lifted its holdings in IDEXX Laboratories by 4.3% in the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after acquiring an additional 23,582 shares during the last quarter. Finally, Alyeska Investment Group L.P. grew its position in IDEXX Laboratories by 97.3% in the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after acquiring an additional 197,808 shares during the period. Institutional investors own 87.84% of the company’s stock.

Trending Headlines about IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates. IDEXX reported quarterly EPS of approximately $3.96–$3.98, above the $3.71 consensus, while revenue rose about 10% year over year to $1.21 billion versus expectations of $1.19 billion. Recurring diagnostics revenue to veterinarians increased 11%, highlighting continued demand for the company’s core testing services. IDEXX Laboratories Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: FY 2026 guidance was raised. Management now expects EPS of $14.96–$15.16, above the $14.86 analyst consensus, and revenue of $4.7 billion–$4.8 billion, generally in line with expectations. The higher profit outlook was a major catalyst for the stock’s gains following the report. IDEXX Raises Forecast
• Positive Sentiment: Analyst and technical signals remain favorable. Morgan Stanley reiterated its Buy rating and $805 price target, citing strong execution and the raised outlook. Separately, IDXX moved above its 200-day moving average, a technical signal often interpreted as evidence of improving long-term momentum. Buy Reiterated on Strong Execution
• Negative Sentiment: Some concerns remain about underlying demand and margins. The improved profit forecast does not appear to be driven by stronger veterinary visits, and commentary indicated that the margin outlook has softened. Investors may therefore watch whether diagnostics growth can continue to offset weaker clinic traffic and sustain the elevated valuation.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.